Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Immutep Ltd.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
In this second instalment on key trends playing out in India, Scrip talks to industry leaders on the marked shift in GMP norms that could potentially resize Indian manufacturing, large player interest in the CDMO space and M&A activity, where PE firms may be the “most aggressive” buyers.
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Immutep S.A.S.
- Immutep GmbH
- Immutep, U.S., Inc.
- Prima BioMed Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.